Spero Therapeutics (STU:2HA) E10: €-2.55 (As of Mar. 2026)


STU:2HA Spero Therapeutics Inc STU:2HA
48 GF Score
Price €1.96
GF Value €0.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics E10?

Spero Therapeutics STU:2HA +11.21% 48 E10 is €-2.55 as of Mar. 2026. GuruFocus rates STU:2HA with a GF Score™ of 48/100 and a GF Value™ of €0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Spero Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.112. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-2.55 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Spero Therapeutics's current stock price is €1.964. Spero Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-2.55. Spero Therapeutics's Shiller PE Ratio of today is .


Spero Therapeutics  (STU:2HA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Spero Therapeutics E10 Related Terms


Spero Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics E10 Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2.55

STU:2HA vs VXRT, ADCT, GNLX: E10 Comparison

For the Biotechnology subindustry, Spero Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Shiller PE Ratio falls into.


STU:2HA
48GF Score
Spero Therapeutics Inc STU:2HA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spero Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.112/330.2130*330.2130
=-0.112

Current CPI (Mar. 2026) = 330.2130.

Spero Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201609 -1.000 241.428 -1.368
201612 -1.196 241.432 -1.636
201703 -1.009 243.801 -1.367
201706 -1.633 244.955 -2.201
201709 -0.756 246.819 -1.011
201712 -1.344 246.524 -1.800
201803 -0.600 249.554 -0.794
201806 -0.591 251.989 -0.774
201809 -0.514 252.439 -0.672
201812 -0.527 251.233 -0.693
201903 -0.257 254.202 -0.334
201906 -0.655 256.143 -0.844
201909 -0.863 256.759 -1.110
201912 -1.188 256.974 -1.527
202003 -1.104 258.115 -1.412
202006 -0.755 257.797 -0.967
202009 -0.730 260.280 -0.926
202012 -0.559 260.474 -0.709
202103 -0.554 264.877 -0.691
202106 -0.523 271.696 -0.636
202109 -0.595 274.310 -0.716
202112 -0.814 278.802 -0.964
202203 -0.917 287.504 -1.053
202206 -0.823 296.311 -0.917
202209 -0.333 296.808 -0.370
202212 0.519 296.797 0.577
202303 -0.233 301.836 -0.255
202306 -0.212 305.109 -0.229
202309 -0.056 307.789 -0.060
202312 0.889 306.746 0.957
202403 -0.221 312.332 -0.234
202406 -0.307 314.175 -0.323
202409 -0.288 315.301 -0.302
202412 -0.363 315.605 -0.380
202503 -0.231 319.799 -0.239
202506 -0.026 322.561 -0.027
202509 -0.111 324.800 -0.113
202512 0.453 324.054 0.462
202603 -0.112 330.213 -0.112

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-2.55 mean?
Spero Therapeutics (STU:2HA) has a E10 of €-2.55 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' E10 too high?
Spero Therapeutics' current E10 is €-2.55. Overall, Spero Therapeutics has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' E10 compare to VXRT and ADCT?
Spero Therapeutics' E10 of €-2.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current E10 is €-2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (STU:2HA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.96 — trading 113.5% above its estimated fair value. The current E10 is €-2.55. Spero Therapeutics' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Spero Therapeutics (STU:2HA), the current E10 is €-2.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (STU:2HA) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of €1.96 is trading 113.5% above its estimated GF Value™ of €0.92. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:2HA:

  • E10: €-2.55
  • GF Value™: €0.92 vs. price of €1.96 (113.5% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the STU:2HA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Other Exchanges SPRO:USA
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
48GF Score

Get the complete analysis for STU:2HA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.96
Price
€0.92
GF Value